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Figure 1. Commercially available lead (1) ana b s t r a c t
A series of fused tricyclic mGluR1 antagonists containing a pyridone ring were synthesized. In vitro, these
antagonists were potent against both human and rat isozymes, as well as selective for inhibiting mGluR1
over mGluR5. When dosed orally, several examples were active in vivo in a rat SNL test.
 2012 Elsevier Ltd. All rights reserved.N S
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c or dMetabotropic glutamate receptors (mGluRs) are G-protein cou-
pled receptors (GPCRs) located primarily in the nervous system.1
These receptors possess a highly conserved, extracellular gluta-
mate binding region as well as a transmembrane domain contain-
ing a binding site for noncompetitive, allosteric modulators.2,3
Eight of these receptors have been identified and classified into
three subgroups based on sequence homology and function, with
mGluR1 and R5 comprising group I. Several studies have demon-
strated that mGluR1 knockout animals exhibit reduced sensitivity
to pain, thus identifying mGluR1 as a potential target for treating
neuropathic pain.4,5N S
R
N
O
X
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Figure 2. (a) 3, CuBr2, aq 48% HBr, NaNO2, 39%; (b) 4, I2, t-BuONO, CH3CN, 59%; (c)
(i) 5, (Z)-EtOCHCHSnBu3, i-Pr2NEt, (Ph3P)4Pd, toluene, microwave, 180 C, 20 min,
75%; (ii) aq 1 M HCl, THF, reflux, 75%; (d) (i) 6, (Z)-EtOCHCHSnBu3, i-Pr2NEt,
(Ph3P)2PdCl2, toluene, 110 C; (ii) aq 1 M HCl, THF, reflux, 36% over two steps; (e) 7,
cyclohexylamine, HOAc, toluene, 110 C, 85%; (f) 7, amine, 3 Å mol sieves, THF,
reflux, 2 h, then NaH, 20–76%; (g) 8, amine, Me3Al, toluene, 110 C, 10–77%.Commercially available, fused tricycle 1 was found to be a po-
tent, in vitro antagonist against both human and rat forms ofll rights reserved.
nnett).mGluR1 (see Fig. 1).6 Furthermore, testing of compound 1 in the
Chung rat spinal nerve ligation (SNL) assay produced an ED50 of
1.2 mg/kg.7 Based on these results, a series of analogs that
combined a left side pyridine or pyrimidine ring with a right side
pyridone (2) were proposed and synthesized.8Starting from known aminoester 3, the amino group was con-
verted to a bromide via a diazonium intermediate and CuBr2 to
provide aryl bromide 5. Stille coupling of 5 with 2-ethoxyvinyl-
stannane, followed by hydrolysis of the resulting enol ether
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Figure 3. (a) (i) 33% HBr in HOAc, 100 C, 85–89%; (ii) POCl3, 115 C, 50–87%; (b)
X = 4-MeO-Ph, 3-F,4-MeO-Ph, or 2-F,4-MeO-Ph; (i) pyridine–HCl, CHCl3, 65 C, 74–
97%; (ii) TsCl, iPr2NEt, dioxane, 65 C, 4 h, then LiCl, Et4NCl, 65 C, 16 h, 40–87%; (c)
amine, DMSO, 65 C, 26–89%.
Table 1
In vitro mGluR1 activity of N,N-dimethylaminopyridyl derivatives 9 and selectivity
versus mGluR59
N S
N
N
O
X
9
Compd X h-mGluR1 IC50
(nM)
h-mGluR5 IC50
(nM)
r-mGluR1 Ki
(nM)
9a 4-MeO-Ph 6.3 4624 17
9b 4-Me-Ph 4.7 1201 1.9
9c 4-F-Ph 5.2 >1000 29
9d 4-Cl-Ph 0.4 >10,000 1.9
9e 4-Br-Ph 5.7 7844 0.4
9f 4-CN-Ph 10 >1000 56
9g 4-Et-Ph 8.2 515 18
9h Cyclohexyl 8.1 >10,000 11
9i 3-F,4-MeO-
Ph
3.9 >1000 13
9j 2-F,4-MeO-
Ph
14 >1000 19
9k
S
N
5.0 1321 11
9l
N
S
3.1 >10,000 12
Table 2
In vitro mGluR1 activity of 4-methoxypyridyl derivatives 109
N S
OMe
N
O
X
10
Compd X h-mGluR1 IC50 (nM) r-mGluR1 Ki (nM)
10a 4-MeO-Ph 6.3 6.5
10b 3-MeO-Ph 118 566
10c 2-MeO-Ph >1000 >1000
10d 2-Me-Ph 85 204
10e 2-Me,4-MeO-Ph 54 32
10f 4-Et-Ph 35 42
10g 4-Cyclopropyl-Ph 79 119
10h Cyclohexyl 5.4 14
10i Ethyl >1000 778
Table 3
In vitro mGluR1 activity of 4-methoxyphenyl derivatives 129
N S
R
N
O
OMe
12
Compd R h-mGluR1 IC50 (nM) r-mGluR1 Ki (nM)
9a Me2N 6.3 17
10a MeO 6.3 6.5
12a HO >1000 >1000
12b MeNH 27 18
12c EtNH 15 8.4
12d n-PrNH 55 24
12e Cyclopropylamino 12 5.2
12f HOCH2CH2NH 124 136
12g MeOCH2CH2NH 192 108
12h NH
HO
133 86
12i
HO N
Me
17 63
1576 C. E. Bennett et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1575–1578afforded aldehyde 7. This intermediate was then treated with var-
ious amines to give fused tricycles 9. As an initial comparison to
the original lead 1, the N,N-dimethylamino derivatives 9 listed in
Table 1 were synthesized. Happily, most derivatives were very po-
tent antagonists of both the human and rat versions of mGluR1
(Table 1). Additionally, these molecules were very selective for
h-mGluR1 over h-mGluR5, with selectivities typically greater than
100 to 1. From these analogs, it is readily apparent that para-
substituted phenyl rings are well tolerated (9a–g), as well as a sat-
urated cyclohexyl ring (9h). Additional, small substitutions such as
fluorines (9i–j) or benzthiazoles (9k–l) also afforded potent
inhibitors.
To further examine the SAR on the right side of this pyridone
series, methoxypyridine derivatives 10 (Table 2) were synthesized
in a manner analogous to that used for 9 (Fig. 2). These derivatives
quickly established the patterns and size of substitutions tolerated
by mGluR1. Not surprisingly, the para-methoxyphenyl analog 10a
was quite potent. Moving the methoxy group to themeta- and then
ortho-positions (10b–c), however, resulted in a 20-fold and >150-
fold drop in IC50, respectively. Replacing the ortho-methoxy group
of 10c with a methyl substituent provided compound 10d with an
IC50 of 85 nM, albeit with slightly reduced rat potency. The combi-nation of ortho-methyl and para-methoxy substituents (10e) affor-
ded good human and rat potency. From this set of data (10a–e), it
is clear that only small groups are tolerated at themeta- and ortho-
positions. The para-position of the appended phenyl ring also only
tolerated small groups. While the para-methoxyphenyl group of
10a provided a potent inhibitor, the para-ethyl group of 10f and
the para-cyclopropyl group of 10g resulted in 5-fold and 12-fold
drops in IC50, respectively. Replacing the phenyl ring substituent
with a cyclohexane ring (10h, IC50 = 5.4 nM) did not cause a loss
in potency. Reducing the size of the alkyl group to an ethyl (10i),
however did result in a >150-fold drop in IC50, relative to 10a
and 10h. Gratifyingly, the mGluR1 human IC50’s and rat Ki’s mir-
rored each other for each substrate. The data in Tables 1 and 2
clearly indicate that the right hand side substituent binds in a
space in which phenyl rings substituted with small groups fit well,
but groups significantly larger (10f) or smaller (10i) are not
tolerated.
With the size requirements of the right side substituent estab-
lished, we examined next the effects of substituent changes at the
4-position of the left side pyridine. For these studies, a series of
4-methoxypyridine derivatives (10) were converted to their corre-
sponding 4-chloropyridine analogs (11), as shown in Figure 3.
These 4-chloropyridine intermediates were used to introduce var-
ious amines into the 4-position of the pyridine ring. Typically, this
transformation was achieved by treating a 4-methoxypyridine
with HBr in acetic acid, and then converting the resulting 4-
hydroxypyridine into a 4-chloropyridine with POCl3. When the
right side substituent X was a methoxy substituted phenyl ring,
milder conditions had to be used. In these cases, the 4-methoxy-
pyridine was demethylated with excess pyridine–HCl in
chloroform at 65 C to provide a 4-hydroxypyridine. This resulting
hydroxyl group was sulfonylated with p-toluenesulfonyl chloride,
and then the tosylate was displaced with chloride ion to provide
Table 4
In vitro mGluR1 activity of N methylaminopyridyl derivatives 139
N S
HN
N
O
X
13
Me
Compd R h-mGluR1 IC50 (nM) r-mGluR1 Ki (nM)
13a 4-Me-Ph 3.4 16
13b 4-F-Ph 68 270
13c 4-Cl-Ph 2.0 13
13d 4-Br-Ph 0.8 6.1
13e 4-CN-Ph 203 309
13f 3-F,4-MeO-Ph 75 40
13g 2-F,4-MeO-Ph 88 32
13h
S
N
47 71
Table 5
In vitro mGluR1 activity of 4-ethylamino- and 4-cyclopropyl aminopyridyl derivatives
149
N S
R
N
O
X
14
Compd R X h-mGluR1 IC50 (nM) r-mGluR1 Ki (nM)
14a EtNH Me 7.7 9.6
14b Cyclopropylamino Me 9.8 12
14c EtNH Cl 3.0 9.4
14d Cyclopropylamino Cl 4.4 7.3
14e EtNH Br 2.0 7.3
14f Cyclopropylamino Br 2.3 3.3
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Figure 4. (a) I2, t-BuONO, CH3CN, 51%; (b) (Z)-EtOCHCHSnBu3, Pd2(dba)3, DMF,
80 C, 77%; (c) aq 1 M HCl, THF, reflux, 40%; (d) aniline, 3 Å mol sieves, THF, reflux,
2 h, then NaH, 13–68%; (e) aniline, Me3Al, toluene, 110 C, 70%; (f) X = Me, amine,
DMSO, 50 C, 23–88%; (g) X = OMe, pyridine–HCl, CHCl3, 65 C, 52%; (h) 2,4,6-tri-
iso-propylbenzenesulfonyl chloride, DMAP, iPr2NEt, CHCl3, 1 h, then amine, 5–31%.
Table 6
In vitro mGluR1 activity of A-ring pyrimidyl, C-ring pyridonyl derivatives 179
N
N S
R
N
O
X
17
Compd R X h-mGluR1 IC50
(nM)
r-mGluR1 Ki
(nM)
17a Me2N MeO 6.4 19
17b MeNH MeO 88 77
17c EtNH MeO 34 32
17d Cyclopropylamino MeO 15 13
17e Me2N Me 6.7 28
17f MeNH Me 31 97
17g EtNH Me 15 52
17h Cyclopropylamino Me 12 22
C. E. Bennett et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1575–1578 15774-chloropyridine analogs (11). Treatment of these 4-chloropyri-
dine analogs (11) with various amines in DMSO afforded the
desired 4-aminopyridine compounds.
The initial amine scan of the 4-position of the pyridine ring was
conducted with para-methoxyphenyl substituted tricycle 12. For
comparison, previously described derivatives 9a and 10a are listed
in Table 3, with 9a used as the point of reference. In the course of
generating these analogs, 4-methoxypyridine 10awas demethylat-
ed to provide hydroxypyridine 12a. The net result of this demeth-
ylation was a >150-fold decrease in mGluR1 antagonism compared
to 10a. Methylamino- and ethylamino-derivatives 12b and 12c
exhibited only slight increases in h-mGluR1 IC50, while remaining
equipotent or more potent at the rat isozyme, compared to 9a.
Increasing the length of the alkyl chain to n-propyl (12d), resulted
in a 9-fold decrease in h-mGluR1 potency. Interestingly, cyclopro-
pylamino-derviative 12e was very potent against both human and
rat isozymes (IC50 = 12 nM and Ki = 5.2 nM, respectively). Replacing
the terminal methyl group of 12d with hydroxyl and methoxy
groups provided derivatives 12f and 12g, which exhibited
20- and 30-fold loss in h-mGluR1 activity, respectively. While sec-
ondary alcohol analog 12h showed no improved potency over 12f,
secondary amino-derivative 12i did show improved potency
against the human isozyme (IC50 = 17 nM). From this data, it seems
clear that only amines substituted with small alkyl groups are well
tolerated at the 4-pyridyl position of 12. As a result, we limited
substitution at this position to methylamino-, N,N-dimethyl-
amino-, ethylamino-, or cyclopropylamino-groups during our
future SAR development.
Next, we decided to combine the aforementioned small alkyl
amino substituents with the best right side aryls groups from
Tables 1 and 2. From the data in Table 4, it can be seen thatpara-methyl-, -chloro-, and -bromo-phenyl substitutions (13a,
13c, and 13d) were by far the most potent against both the human
and rat isozymes (Table 4). These same results were also seen
when the left side pyrindine was substituted at the 4-position with
either ethylamine or cycloproplyamine. Only the data for the most
potent derivatives with para-methyl-, -chloro-, and -bromo-phenyl
substitutions are listed in Table 5. As shown, these examples were
consistently potent against both the human and rat isozymes.
Starting from known aminoester 15 (Fig. 4), tricycles 16 with a
left side pyrimidine ring were synthesized in the same manner as
tricycles 10 (Fig. 2). For derivatives 17f and 17g, treatment of the
corresponding intermediate 16 (X = Me) with either methylamine
or ethylamine provided the desired products. For all other cases,
the methyl ether of the pyrimidyl ring was cleaved to afford
hydroxypyrimidine 18. This hydroxyl group was then activated
as a sulfonate ester and displaced with amines to provide analogs
17a–e,h.
From the results in Table 6, it can be seen that N,N-dimethyl-
amino- and cyclopropylamino-derivatives provided the greatest
potency at both the human and rat isozymes. Surprisingly, the
methylamino derivatives 17b and 17f were the least potent, with
the ethylamino analogs in between the two groupings.
A number of the molecules presented here were tested in the
rat spinal nerve ligation (SNL) assay.7 Two of the best results were
obtained for compounds 9a and 12e (Fig. 5). Both moleculesprovided a 50% reversal of the allodynic response at their
corresponding Cmax’s when dosed at 10 mpk (po). From rat PK
experiments, significant demethylation occurred with 9a. Indeed,
a M-14 metabolite was present in a 6-fold excess over parent.
N S
N
N
O
OMe
9a
Rat SNL (10 mpk, p.o.):
50% reversal @ 2h
Rat PK (10 mpk, p.o.):
Parent 9a:
AUC = 873 ng-h/mL
B/P @ 6 h = 0.3
M-14 Metabolite:
AUC = 5475 ng-h/mL
B/P @ 6 h = 0.12
N S
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N
O
OMe
12e
Rat SNL (10 mpk, p.o.):
50% reversal @ 3 h
Rat PK (10 mpk, p.o.):
AUC = 8866 ng-h/mL
B/P @ 6 h = 0.2
Figure 5. In vivo data for compounds 9a and 12e.
1578 C. E. Bennett et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1575–1578Demethylation was not observed with 12e, suggesting that 9a was
being demethylated at nitrogen.
In summary, a series of fused tricyclic mGluR1 antagonists con-
taining a pyridone ring were synthesized. In vitro, many of these
compounds proved to be potent against both human and rat iso-
zymes, as well as selective for inhibiting mGluR1 over mGluR5.
Several of these molecules were active in vivo when dosed orally.The best examples were capable of providing a 50% reversal in
the rat SNL test.
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